Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers

ISSN: 1875-6301 (Online)
ISSN: 1573-3947 (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Cancer Therapy Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Kurt S. Zaenker
Institute of Immunology and Experimental Oncology University Witten/Herdecke
Stockumerstraße 10, 58448 Witten
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers

Author(s): Ana Paula Delgado, Pamela Brandao, Sheilin Hamid and Ramaswamy Narayanan

Affiliation: Department of Biological Sciences, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL 33431.

Abstract

The post genome era has ushered us into therapeutic target discovery empowering us to mine the genome using rational approaches. Numerous cancer targets have emerged from the genome project for diagnostics, therapeutics and response to therapy prediction. Among thousands of genes predicted in the human genome, nearly half of them remain uncharacterized. Considerable attention in the last decade has focused on the well-characterized known genes. However, the future of cancer target discovery resides in the uncharacterized or novel genes called the dark matter of the human genome. Realizing the importance of this vast untapped potential, recently the US National Cancer Institute announced a new initiative called "Illuminating the Dark Matter of the Genome for Druggability". This area of cancer research albeit exciting, remains a challenge due to the lack of adequate information about the uncharacterized genes. Amongst the plethora of bioinformatics tools and databases, a streamlined approach remains elusive. In this review, we present a simplified approach to mine directly the cancer proteome for rapid target discovery. Using such an approach, we have created a database of uncharacterized cancer genes and have shown the biomarker and drug target potential for an uncharacterized protein, C1ORF87, as a putative solid tumor target. In view of this protein's association with carcinomas, the C1ORF87 is termed as Carcinoma-Related EF-Hand (CREF) gene. The approaches discussed in this review should aid in lighting the dark matter of the human cancer proteome.

Keywords: Post genome, druggable genes, uncharacterized genes, C1ORF87, CREF gene.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 9
Issue Number: 4
First Page: 265
Last Page: 277
Page Count: 13
DOI: 10.2174/1573394710666140313003905
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science